SCHEMBL4481625

SCHEMBL4481625

Cc1c(C)c2c(c(C)c1O)C(=O)CC1(CCC1)O2

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
PTPN1 P18031 3/20 0.36
ALOX5 P09917 1/20 0.31
ALDH1A1 P00352 3/20 0.30
HPGD P15428 2/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
KLK7 P49862 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464207 0.84 PTPN1 (0.35) KDM4EPTGS1PTGS2CYP1A2CYP3A4
SCHEMBL5267649 0.80 ALDH1A1 (0.44) KDM4EPTGS1PTGS2CYP1A2CYP3A4
SCHEMBL4473243 0.78 PTGS1 (0.33) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL4468788 0.78 KMT2A (0.38) KDM4EHTTATMALOX5ALDH1A1
SCHEMBL4466020 0.76 KDM4E (0.46) KDM4ETSHRHTTATMALDH1A1
SCHEMBL4466400 0.74 KDM4E (0.33) KDM4EHTTATMALDH1A1HPGD
SCHEMBL4466588 0.73 PTGS1 (0.36) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL4473238 0.73 KDM4E (0.43) KDM4ETSHRHTTATMPTPN1
SCHEMBL4465411 0.72 PTGS1 (0.35) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL2784524 0.72 PTGS1 (0.33) KDM4EPTGS1PTGS2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 KDM4E 3310/4885PTGS1 24/4885PTGS2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.